Credit Suisse Group set a €82.00 ($95.35) target price on Sanofi (EPA:SAN) in a research report sent to investors on Friday morning. The firm currently has a buy rating on the stock.

A number of other brokerages also recently commented on SAN. Barclays set a €80.00 ($93.02) target price on Sanofi and gave the company a neutral rating in a research note on Thursday, November 1st. Cfra set a €87.00 ($101.16) price target on Sanofi and gave the stock a buy rating in a research note on Thursday, November 1st. Bank of America set a €95.00 ($110.47) price target on Sanofi and gave the stock a buy rating in a research note on Friday, December 14th. Jefferies Financial Group set a €90.00 ($104.65) price target on Sanofi and gave the stock a buy rating in a research note on Tuesday, December 11th. Finally, Morgan Stanley set a €79.00 ($91.86) price target on Sanofi and gave the stock a neutral rating in a research note on Friday, December 14th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Sanofi has a consensus rating of Buy and a consensus price target of €85.38 ($99.27).

Sanofi has a 52 week low of €63.09 ($73.36) and a 52 week high of €92.97 ($108.10).

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: Can systematic risk be avoided?

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.